Impact of SARS-CoV-2 infection in patients with cardiac amyloidosis: Results of a multicentre registry

José M Larrañaga-Moreira; Ana I Rodriguez-Serrano; Fernando Domínguez; Andrea Lalario; Esther Zorio; Roberto Barriales-Villa; Dilemma International Cardiomyopathy, Heart Failure Registry Investigators Group

doi:10.1016/j.medcli.2023.06.025

Impact of SARS-CoV-2 infection in patients with cardiac amyloidosis: Results of a multicentre registry

Med Clin (Barc). 2023 Dec 7;161(11):476-482. doi: 10.1016/j.medcli.2023.06.025. Epub 2023 Sep 6.

[Article in English, Spanish]

Authors

José M Larrañaga-Moreira¹, Ana I Rodriguez-Serrano², Fernando Domínguez³, Andrea Lalario⁴, Esther Zorio⁵, Roberto Barriales-Villa⁶; Dilemma International Cardiomyopathy, Heart Failure Registry Investigators Group

Affiliations

¹ Unidad de Cardiopatías Familiares, Instituto de Investigación Biomédica de A Coruña (INIBIC), Hospital Universitario de A Coruña (HUAC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, Spain. Electronic address: [email protected].
² Hospital Universitario Virgen de Arrixaca, Murcia. Spain; European Reference Networks for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, The Netherlands.
³ European Reference Networks for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, The Netherlands; Unidad Cardiopatias Familiares, Hospital Universitario Puerta Hierro Majadahonda, IDIPHISA, Madrid, Spain; Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain.
⁴ Cardiovascular Department 'Ospedali Riuniti' and University of Trieste, Trieste, Italy.
⁵ Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain; Unidad Cardiopatías Familiares, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
⁶ Unidad de Cardiopatías Familiares, Instituto de Investigación Biomédica de A Coruña (INIBIC), Hospital Universitario de A Coruña (HUAC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, Spain; Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain.

PMID: 37684159
DOI: 10.1016/j.medcli.2023.06.025

Abstract

Background: Descriptions on impact of SARS-CoV-2 infection in patients with cardiac amyloidosis (CA) are lacking. Our aim was to describe the prognosis of those patients.

Methods: Retrospective observational study of unvaccinated patients with CA who developed SARS-CoV-2 infection enrolled in eleven centres (March 2020 to May 2021). Descriptive analysis of basal characteristics, hospitalization, mortality, and severe clinical course was performed. Comparisons to a population-based control group were made.

Results: Forty-one patients were identified. Most patients had wild-type transthyretin CA (61%) and were on NYHA Class II-III (80.5%). CA patients were commonly hospitalized (73.2%) and those were more symptomatic than outpatients (p=0.035). The 24.4% of CA patients died as consequence of SARS-CoV-2 infection. Patients with CA had an increased risk of hospitalization [OR 6.23 (3.05-12.74), p<0.001] and mortality [OR 2.18 (1.01-4.68), p=0.047] when compared to control population after adjustment by age and sex. After a medium follow-time of 311 days, 41.5% of the CA cohort died.

Conclusions: SARS-CoV-2 infection is associated with high mortality and hospitalization rates in patients with CA, which exceed that expected by their sex and advanced age.

Keywords: Amiloidosis cardíaca; COVID-19; Cardiac amyloidosis; Heart failure; Infección por SARS-CoV-2; Insuficiencia cardíaca; Prognosis; Pronóstico; Registries; Registro; SARS-CoV-2 infection.

Publication types

Observational Study
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Amyloidosis*
COVID-19* / complications
Hospitalization
Humans
Registries
SARS-CoV-2